AMP-945 is under clinical development by Amplia Therapeutics and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase II drugs for Metastatic Adenocarcinoma of The Pancreas have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AMP-945’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMP-945 (CTX-0294945) is under investigation for the treatment of idiopathic pulmonary fibrosis, pancreatic ductal adenocarcinoma, metastatic pancreatic cancer, fibrotic Interstitial Lung Diseases, non-alcoholic steatohepatitis (NASH) and squamous cell carcinoma. It is a small molecule administered through oral route. It acts by targeting focal adhesion kinase (FAK).
It was also under development for the treatment of triple negative breast cancer.
Amplia Therapeutics overview
Amplia Therapeutics, formerly Innate Therapeutics Ltd, is a pharmaceutical company. The company focuses on the development of focal adhesion kinase (FAK) inhibitors for the treatment of cancer and fibrosis. It lead drug candidate, AMP945, is a small molecule targeting focal adhesion kinase (FAK) in fibrotic tumors such as pancreatic and ovarian cancer; and the other drug candidate AMP886 is a multi-action molecule targeting VEGFR3 and FLT3 cancer pathways in solid and hematological cancers. As FAK is a significant target in cancer immunology, the company has focus on FAK inhibitors for treating cancers and chronic diseases such as idiopathic pulmonary fibrosis. Amplia Therapeutics is headquartered in North Melbourne, Victoria, Australia.
For a complete picture of AMP-945’s drug-specific PTSR and LoA scores, buy the report here.